4D Molecular Therapeutics, Inc., a clinical-stage biotherapeutics company, develops genetic medicines using its therapeutic vector evolution platform in the Netherland and the United States. The company develops a portfolio of genetic medicine product candidates focuses in three therapeutic areas for ophthalmology, cardiology, and pulmonology. Its product pipeline includes 4D-150, which is in phase 1/2 clinical trial for the treatment of wet age-related macular degeneration; and is in phase 1/2 clinical trial for the treatment of diabetic macular edema. The company develops 4D-125, which is in phase 1/2 clinical trial for the treatment of x-linked retinitis pigmentosa; 4D-110, which is in phase 1/2 clinical trial for the treatment of choroideremia; 4D-710, which is in phase 1/2 clinical trial for the treatment cystic fibrosis lung disease; and 4D-310 to treat fabry disease cardiomyopathy and is in phase 1/2 clinical trial. In addition, its product candidates comprises 4D-175, which is in pre-clinical development for the treatment for geographic trophy; and 4D-725 to treat alpha-1 antitrypsin deficiency lung disease and is in pre-clinical development. The company has collaboration and licensing agreements with Arbor Biotechnologies, Inc.; Astellas Gene Therapies, Inc; uniQure biopharma B.V.; and Cystic Fibrosis Foundation. 4D Molecular Therapeutics, Inc. was founded in 2013 and is headquartered in Emeryville, California.
| 18.35 | |
| 18.8 | |
| - | |
| 19.33 | |
| 18.22 | |
| 9.44-36.25 | |
| 958 M | |
| 51 703 K | |
| 20 453 K | |
| -0.66 | |
| 2.82 |
No long-term obligations. The minimum period is one month only. No wait. You get an API key with instructions in a few seconds right after subscription.
4D Molecular Therapeutics, Inc. Initial interim landmark data analysis (N=50 at 24 Weeks) will be presented byArshad M. Khanani, M.D., M.A., FASRS, Principal Investigator of the PRISM clinical trial ...
On January 23, 2024, David Kirn, CEO of 4D Molecular Therapeutics Inc (NASDAQ:FDMT), sold 5,696 shares of the company's stock, according to a recent SEC Filing. This transaction is part of a series of...
Our 24/7 support would be happy to assist you via chat or email:
support@eodhistoricaldata.comVisit also:
